Page 176 - Cardiac Nursing

e 1
qxd
Apt
ara
8:2
52
52
009
9/2
2-1
p13
52.
52.
5 A
P
g
M
P
9/0
K34
K34
06_
0-c
L L LWB K34 0-c 06_ p13 2-1 52. qxd 0 9/0 9/2 009 0 0 8:2 5 A M P a a g e 1 52 Apt ara
0
LWB
LWBK340-c06_06_p132-152.qxd 09/09/2009 08:25 AM Page 152 Aptara
152 PA R T I I / Physiologic and Pathologic Responses
nausea and vomiting to acute abdominal pain. Assessment of the 17. Wood, K. E. (2002). Major pulmonary embolism: Review of a patho-
abdomen, as well as monitoring trends in liver function test, physiologic approach to the golden hour of hemodynamically significant
pulmonary embolism. Chest, 121, 877–905.
should never be omitted and given special attention if HIT is sus- 18. Crowther, M. A. (2005). Venous thromboembolism. In R. S. Hoffman, E.
pected. Any abdominal discomfort should be carefully considered Benz, S. Shattil, et al. (Eds.), New York: Churchill-Livingstone.
and monitored for any progression. Monitoring urine output for at 19. Hull, R. D., Pineo, G., & Raskob, G. (2000). Diagnosis and treatment of
least 0.5 to 1 mL/kg per hour should be routine practice. The venous thromboembolism. In A. Grenvik, S. Ayres, P. Holbrook, et al.
(Eds.), Textbook of critical care medicine. Philadelphia: WB Saunders.
BUN and creatinine trends should also be closely reviewed. If these 20. Geerts, W. H., Pineo, G. F., Heit, J. A., et al. (2004). Prevention of venous
organ systems are severely compromised, multisystem organ dys- thromboembolism: The Seventh ACCP Conference on Antithrombotic
function may be the end result, with poor outcomes. HIT can be and Thrombolytic Therapy. Chest, 126, 338S–400S.
6
6
a devastating syndrome. 21. Francis, C., & Kaplan, K. (2006). Principles of antithrombotic therapy. In
M. Lichtman, E. Beutler, T. Kipps, et al. (Eds.), Williams hematology. New
York: McGraw-Hill.
REFERENCES 22. Brunton, L., Lazo, J., & Parker, K. (2006). Goodman & Gilman’s the phar-
macologic basis of therapeutics. New York: McGraw-Hill.
1. Lichtman, M., Beutler, E., Kipps, T., et al. (2006). Williams hematology. 23. Dalen, J. E. (2002). Pulmonary embolism: What have we learned since
New York: McGraw-Hill. Virchow? Treatment and prevention. Chest, 122, 1801–1817.
g
g
2. Proceedings of the Third Margaux Conference on Critical Illness: The 24. Fahey, V. (1999). Vascular nursing. Philadelphia: WB Saunders.
Endothelium—An Underrecognized Organ in Critical Illness? Sedona, 25. Goldhaber, S. Z., Visani, L., & De Rosa, M. (1999). Acute pulmonary
Arizona, USA. November 14–18, 2001. (2002). Critical Care Medicine, embolism: Clinical outcomes in the International Cooperative Pulmonary
30, S179–S348. Embolism Registry (ICOPER). Lancet, 353, 1386–1389.
3. Libby, P., Ridker, P. M., & Maseri, A. (2002). Inflammation and athero- 26. Goldhaber, S. Z. (2005). Deep vein thrombosis and pulmonary throm-
sclerosis. Circulation, 105, 1135–1143. boembolism. In A. Fauci, E. Braunwald, D. Kasper, et al. (Eds.), Harrison’s
4. Hoffman, R. S., Benz, E., Shattil, S., et al. (2005). Hematology: Basic phys- principles of internal medicine. New York: McGraw-Hill.
iology and practice. Philadelphia: Churchill-Livingstone. 27. Bartorelli, A. L., & Marenzi, G. (2008). Contrast-induced nephropathy.
5. Turgeon, M. (2005). Clinical hematology: Theory and procedures. Philadelphia: Journal of Interventional Cardiology, 21, 74–85.
Williams & Wilkins. 28. Tepel, M., van der Giet, M., Schwarzfeld, C., et al. (2000). Prevention of
6. Hack, C. E., & Zeerleder, S. (2001). The endothelium in sepsis: Source of radiographic-contrast-agent-induced reductions in renal function by
and a target for inflammation. Critical Care Medicine, 29, S21–S27. acetylcysteine. New England Journal of Medicine, 343, 180–184.
7. Dellinger, R. P., Levy, M. M., Carlet, J. M., et al. (2008). Surviving Sep- 29. Warkentin, T. E. (1999). Heparin-induced thrombocytopenia: A clinico-
sis Campaign: International guidelines for management of severe sepsis pathologic syndrome. Thrombosis and Haemostasis, 82, 439–447.
and septic shock: 2008. Critical Care Medicine, 36, 296–327. 30. Warkentin, T. E., Chong, B. H., & Greinacher, A. (1998). Heparin-in-
6
6
8. Bernard, G. R., Vincent, J. L., Laterre, P. F., et al. (2001). Efficacy and duced thrombocytopenia: Towards consensus. Thrombosis and Haemostasis,
safety of recombinant human activated protein C for severe sepsis. New 79, 1–7.
4
4
England Journal of Medicine, 344, 699–709. 31. Warkentin, T. E. (2007). Heparin-induced thrombocytopenia. Hematol-
6
6
9. Libby, P. (2002). Atherosclerosis: The new view. Scientific American, 286, ogy and Oncology Clinics of North America, 21, 589–607, v.
46–55. 32. Warkentin, T. E. (2002). Platelet count monitoring and laboratory testing
10. Owen, D., & Webster, J. (1998). Hematology: Clinical physiology AACN for heparin-induced thrombocytopenia. Archives of Pathology and Labora-
6
6
g
g
clinical reference for critical care nursing. St. Louis: CV Mosby. tory Medicine, 126, 1415–1423.
11. Merten, G. J., Burgess, W. P., Gray, L. V., et al. (2004). Prevention of 33. Tortora, G., & Grabowski, S. (2003). Principles of anatomy and physiology.
contrast-induced nephropathy with sodium bicarbonate: A randomized New York: John Wiley & Sons.
controlled trial. Journal of the American Medical Association, 291, 34. Price, E. A., Hayward, C. P., Moffat, K. A., et al. (2007). Laboratory test-
2328–2334. ing for heparin-induced thrombocytopenia is inconsistent in North America:
12. Liebman, H., & Weltz, I. (2005). Disseminated intravascular coagulation. A survey of North American specialized coagulation laboratories. Throm-
In R. S. Hoffman, E. Benz, S. Shattil, et al. (Eds.), Williams hematology. bosis and Haemostasis, 98, 1357–1361.
New York: Churchill-Livingstone. 35. Warkentin, T. E., & Greinacher, A. (2004). Heparin-induced thrombocy-
13. Hebert, P. C. (1999). Anemia and red cell transfusion in critical care. topenia: Recognition, treatment, and prevention: The Seventh ACCP
Transfusion requirements in Critical Care Investigators and the Canadian Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126,
6
6
Critical Care Trials Group. Minerva Anestesiologica, 65, 293–304. 311S–337S.
14. Goodnough, L. T., & Shander, A. S. (2007). Recombinant factor VIIa:
4
4
Safety and efficacy. Current Opinion in Hematology, 14, 504–509.
15. O’Connell, K. A., Wood, J. J., Wise, R. P., et al. (2006). Thromboembolic W E BSI TE S
adverse events after use of recombinant human coagulation factor VIIa.
Journal of the American Medical Association, 295, 293–298. www.accp.org (especially for guidelines for prophalaxis and treatment of
16. Grenvik, A., Ayres, S., Holbrook, P., et al. (2000). Textbook of critical care. DVT, PE, and HIT)
Philadelphia: WB Saunders. www.guidelines.gov